Pacira BioSciences (PCRX) 10-Q2017 Q2 Quarterly report

Filed: 2 Aug 17, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. junior Avg

New words: administered, admixed, advisory, arm, ceased, colorectal, decision, discontinuation, discontinue, discontinued, discontinuing, endpoint, exit, HCl, Journal, logistic, mg, negatively, Overview, persistent, plant, procedure, profile, prolonged, published, regression, rescue, resubmission, showed, sublease, TAP, thousand

Removed: AETR, amortization, call, commercialize, decide, initially, initiated, issue, licensed, mix, outlined, patent, patient, provision, stage, team

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

PCRX similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

CERTIFICATION PURSUANT TO 18 U.S.C. §1350

Pursuant to 18 U.S.C. §1350, the undersigned certifies that this Quarterly Report on Form 10-Q of Pacira Pharmaceuticals, Inc. for the quarter ended June 30, 2017, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that the information contained in this report fairly presents, in all material respects, the financial condition and results of operations of Pacira Pharmaceuticals, Inc.



Date:	August 2, 2017	/s/ David Stack
		David Stack
		Chief Executive Officer and Chairman
		(Principal Executive Officer)